Study of blood biomarkers detected in NULISA to stratify the prospective multicenter ALZAN cohort of memory clinic patients according to ATN status, presence of synucleinopathy and diagnosis
This study identifies among the 120 biomarkers many already known to be pathological in AD. However, it also highlights new potential targets, emphasizing the value of this multiplex approach. Further analysis combining multiple biomarkers (ratios) will be useful, along with investigations into the impact of confounding factors such as renal function and pre-analytical treatment. Notably, none of these blood biomarkers were able to differentiate between SSA-positive and negative cases.
Authors
- Mehdi Morchikh
- G. Barnier-Figue
- Christophe Hirtz (ORCID: https://orcid.org/0000-0002-7313-0629)
- Germain U. Busto (ORCID: https://orcid.org/0000-0002-8787-563X)
- Saïd Assou (ORCID: https://orcid.org/0000-0001-6448-7995)
- B. Dupuy
- A. Gabelle
- Constance Delaby (ORCID: https://orcid.org/0000-0002-8606-6814)
- Nicolas Pradeilles
- Florence Perrein
- Marie Duchiron
- Karim Bennys
- Cédric Turpinat
- Sylvain Lehmann
Institutions
- Inserm (FR)
- Université de Montpellier (FR)
- Centre Hospitalier de Perpignan (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Montpellier GenomiX (FR)
- Centre Hospitalier Universitaire de Nîmes (FR)
- Institute for Neurosciences of Montpellier (FR)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_106853
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00